Back to Search Start Over

A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model.

Authors :
Johnston SC
Ricks KM
Lakhal-Naouar I
Jay A
Subra C
Raymond JL
King HAD
Rossi F
Clements TL
Fetterer D
Tostenson S
Cincotta CM
Hack HR
Kuklis C
Soman S
King J
Peachman KK
Kim D
Chen WH
Sankhala RS
Martinez EJ
Hajduczki A
Chang WC
Choe M
Thomas PV
Peterson CE
Anderson A
Swafford I
Currier JR
Paquin-Proulx D
Jagodzinski LL
Matyas GR
Rao M
Gromowski GD
Peel SA
White L
Smith JM
Hooper JW
Michael NL
Modjarrad K
Joyce MG
Nalca A
Bolton DL
Pitt MLM
Source :
Vaccines [Vaccines (Basel)] 2022 May 04; Vol. 10 (5). Date of Electronic Publication: 2022 May 04.
Publication Year :
2022

Abstract

The COVID-19 pandemic has had a staggering impact on social, economic, and public health systems worldwide. Vaccine development and mobilization against SARS-CoV-2 (the etiologic agent of COVID-19) has been rapid. However, novel strategies are still necessary to slow the pandemic, and this includes new approaches to vaccine development and/or delivery that will improve vaccination compliance and demonstrate efficacy against emerging variants. Here, we report on the immunogenicity and efficacy of a SARS-CoV-2 vaccine comprising stabilized, pre-fusion spike protein trimers displayed on a ferritin nanoparticle (SpFN) adjuvanted with either conventional aluminum hydroxide or the Army Liposomal Formulation QS-21 (ALFQ) in a cynomolgus macaque COVID-19 model. Vaccination resulted in robust cell-mediated and humoral responses and a significant reduction in lung lesions following SARS-CoV-2 infection. The strength of the immune response suggests that dose sparing through reduced or single dosing in primates may be possible with this vaccine. Overall, the data support further evaluation of SpFN as a SARS-CoV-2 protein-based vaccine candidate with attention to fractional dosing and schedule optimization.

Details

Language :
English
ISSN :
2076-393X
Volume :
10
Issue :
5
Database :
MEDLINE
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
35632473
Full Text :
https://doi.org/10.3390/vaccines10050717